BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Authors » John Fox

Articles by John Fox

ERB found to play key role in neural stem cell differentiation

Nov. 22, 2017
By John Fox
Estrogen receptor beta (ER-beta) is an important factor that should be considered in the design of new stem cell-based regenerative therapies for neurodegenerative conditions, a new Swedish-American collaborative study has concluded.
Read More

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 20, 2017
By John Fox

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 17, 2017
By John Fox
Researchers at Duke-National University of Singapore (Duke-NUS) Medical School have discovered for the first time that interleukin-11 (IL-11) may be an important therapeutic target for cardiovascular (CV) fibrotic diseases, including heart and renal failure, they reported in the Nov. 13, 2017, edition of Nature.
Read More

Axon assemblies pave way for drug discovery

Nov. 16, 2017
By John Fox

Axon assemblies pave way for drug discovery

Nov. 15, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Axon assemblies pave way for drug discovery

Nov. 13, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Molecular map may hold key to new cancer treatments

Nov. 9, 2017
By John Fox

Molecular map may hold key to new cancer treatments

Nov. 8, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Molecular map may hold key to new cancer treatments

Nov. 7, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Erythropoietin said to induce antiangiogenic drug resistance

Nov. 3, 2017
By John Fox
Previous 1 2 … 28 29 30 31 32 33 34 35 36 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing